NAGE
Niagen Bioscience, Inc.
Biotechnology · Healthcare · United States
2.50
close · 2026-10-29
value
63
cheaper than peers63
quality
88
stronger fundamentals88
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 1.93× | 92 |
| price to book | 2.39× | 65 |
| EV to EBITDA | 19.51× | 47 |
| forward P/E | 26.30× | 36 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 21.8% | 89 |
| debt to equity | 2.8% | 82 |
| operating margin | 2.4% | 81 |
| revenue growth | -4.3% | 31 |
4 of 4 measures available
Facts
| market cap | $198M |
| free cash flow | $1.6M |
| employees | 117 |
| first trade | 2008-06-25 |
| next earnings | 2026-11-04 |
| fundamentals updated | 2026-08-20 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 0.20 | 0.11 | -0.07 | -0.24 |
| free cash flow | $13.2M | $11.9M | $7.0M | -$15.4M |
| net income | $17.4M | $8.6M | -$4.9M | -$16.5M |
| revenue | $129.4M | $99.6M | $83.6M | $72.0M |
| unusual items | $2.0M | $0 | not reported | not reported |